For All The Latest Medical News, Health News, Research News, COVID-19 News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Cardiology News, Epigenetic News, Cancer News, Doctor News, Hospital News

BREAKING NEWS
Source: COVID-19 Drug Research  Apr 04, 2020  4 years, 7 months, 1 week, 3 days, 2 hours, 32 minutes ago

BREAKING! COVID-19 Drug Research: Study Shows That Hydroxychloroquine And Azithromycin Has No Effect On COVID-19 Patients, No Better Than A Dangerous Placebo

BREAKING! COVID-19 Drug Research: Study Shows That Hydroxychloroquine And Azithromycin Has No Effect On COVID-19 Patients, No Better Than A Dangerous Placebo
Source: COVID-19 Drug Research  Apr 04, 2020  4 years, 7 months, 1 week, 3 days, 2 hours, 32 minutes ago
COVID-19 Drug Research: A study just published in a French medical journal provides new evidence that hydroxychloroquine does not appear to help the immune system clear the coronavirus from the body. https://www.sciencedirect.com/science/article/pii/S0399077X20300858?via%3Dihub



The study comes on the heels of two others one in France and one in China that reported some benefits in the combination of hydroxychloroquine and azithromycin for COVID-19 patients who did not have severe symptoms of the virus.(both these studies however were not peer-reveiewed) https://www.medrxiv.org/content/10.1101/2020.03.16.20037135v1

The earlier studies also had lots of discrepancies. https://www.medrxiv.org/content/10.1101/2020.03.31.20048777v1 and https://www.medrxiv.org/content/10.1101/2020.03.22.20040949v1

Many researchers are also warning that COVID-19 patients taking these drugs have a higher risk of heart failure. https://www.medrxiv.org/content/10.1101/2020.04.02.20047050v1 and https://www.thailandmedical.news/news/warning-covid-19-clinical-care-experimental-drugs-being-tried-for-covid-19-can-cause-dangerous-abnormal-heart-rhythms and https://www.thailandmedical.news/news/covid-19-clinical-care-guidelines-to-prevent-drug-induced-prolongation-of-qtc-that-often-results-in-sudden-cardiac-death-in-covid-19-patients

However on Saturday (4th March 2020) the US FDA approved the use of these two antimalarial drugs, hydroxychloroquine and a related medication, chloroquine, for emergency use to treat COVID-19. The drugs were touted by President Trump as a “game changer” for COVID-19.

Many are concerned that this drug has been given too much of a high priority before there is enough evidence to show it is indeed effective.

Already there are other clinical studies that showed it is not effective against COVID-19 as well as several other viruses. https://www.zjujournals.com/med/EN/10.3785/j.issn.1008-9292.2020.03.03
 
Also more significantly, it can have dangerous side effects, as well as giving people false hope. The latter has led to widespread shortages of hydroxychloroquine for patients who need it to treat malaria, lupus and rheumatoid arthritis, the indications for which it was originally approved.

KINDLY HAVE HEART AND HELP! Please help support our site and our initiatives to propel and aid research by making a donation to help sustain the site. Donations are accepted via paypal: https://www.thailandmedical.news/p/sponsorship

The ‘trumped up’ idea that the combination of hydroxychloroquine with an antibiotic drug, azithromycin, was effective against COVID-19 gained more attention after a study published on March 17. This study described a trial of 80 patients carried out by Philippe Gautret in Marseille, France. Although some of their results appeared to be encouraging, it should also be noted that most of their patients only had mild symptoms. Furthermore, 85% of the patients didn’t even have a fever which is one of the major telltale symptoms of the virus, thus suggesting that these patients likely would have naturally cleared the virus without any intervention. https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf

In another study, posted on medRxiv, which has not yet been peer-reviewed, Chinese scientists from Renmin Hospital of Wuhan University, in Wuhan, China, gave hydroxychloroquine to patients with only mild infections who were free of medical issues, similar to the Gautret study. The results showed that the 31 patients who received the drug showed a lessening of their symptoms 24 hours earlier than patients in the control group. In addition, pneumonia symptoms improved in 25 of the 31 patients versus 17 of 31 in the control group. As noted in several of the comments associated with the manuscript, there are issues related to the translation of the paper, thus clouding interpretations of some of the results. The paper also appears to focus more on pneumonia than COVID-19. However, these issues may be cleared up or addressed once the paper finishes the peer-review process. https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2

However both studies have conflicting results.

A second French group, led by Jean-Michel Molina, has now tested the hydroxychloroquine-azithromycin combination treatment in 11 patients at the Hôpital Saint-Louis in Paris, France, and their results were strikingly different. https://www.sciencedirect.com/science/article/pii/S0399077X20300858?via%3Dihub

Similar to the the Marseille study, the Molina trial was also a small pilot study. Molina and colleagues used the same dosing regimen as Gautret. In contrast, however, to the Gautret study, eight of the 11 patients had underlying health conditions, and 10 of 11 had fevers and were quite ill at the time the dosing began.

The French researchers found that after five to six days of treatment with hydroxychloroquine (600 mg per day for 10 days) and azithromycin (500 mg on day 1 and 250 mg on days 2 to 5), eight of the 10 patients still tested positive for COVID-19. Of these 10 patients, one patient died, two were transferred to the ICU and another had to be removed from the treatment due to serious complications.

Furthermore, a similar study in China also showed no difference in viral clearance after seven days either with or without the hydroxychloroquine with the patients in the trial. This supports Molina’s findings. https://www.zjujournals.com/med/EN/10.3785/j.issn.1008-9292.2020.03.03

Many researchers are warning that despite the recent approval of this drug for use against COVID-19, questions remain as to the efficacy of this treatment. As Dr Molina and colleagues note: “Ongoing randomized clinical trials with hydroxychloroquine should provide a definitive answer regarding the alleged efficacy of this combination and will assess its safety.”

We at Thailand Medical News warns all that there is so much fake news and misinformation being released by government agencies and health authorities and even so called pharma and drug companies merely for reasons to pacify the public, for political and security reasons and also for reasons of greed and money.

To date there are no found drugs or pharmaceuticals that can truly cure or treat Covid-19 effectively. Most of these experimental drugs especially the antivirals are actually toxic and have been known to have caused deaths in Covid-19 patients. There are a number of safer drugs and herbs and TCM preparations being researched and undergoing clinical trials and we will be covering on these shortly.

For the latest on Covid-19 drug research, please keep on logging to: Thailand Medical News

KINDLY HAVE HEART AND HELP! Please help support our site and our initiatives to propel and aid research by making a donation to help sustain the site. Donations are accepted via paypalhttps://www.thailandmedical.news/p/sponsorship
 

MOST READ

Nov 05, 2024  9 days ago
Nikhil Prasad
Jul 25, 2024  4 months ago
Nikhil Prasad
Jul 24, 2024  4 months ago
Nikhil Prasad
Jun 10, 2023  1 year ago
COVID-19 News - DNA Methylation - Asymptomatic SARS-CoV-2 Infections
Aug 04, 2022  2 years ago
Source: Medical News - SARS-CoV-2 & Cancer

FROM PHARMA NEWS

LATEST ON MEDICAL STOCK MARKET